ABSTRACT
Tubulin tyrosine ligase 12 (TTLL12) is a promising target for therapeutic intervention since it has been implicated in tumour progression, the innate immune response to viral infection, ciliogenesis and abnormal cell division. It is the most mysterious of a fourteen-member TTL/TTLL family, since, although it is the topmost conserved in evolution, it does not have predicted enzymatic activities. TTLL12 seems to act as a pseudo-enzyme that modulates various processes indirectly. Given the need to target its functions, we initially set out to identify a property of TTLL12 that could be used to develop a reliable high-throughput screening assay. We discovered that TTLL12 suppresses the cell toxicity of nitrotyrosine (3-nitrotyrosine) and its ligation to the C-terminus of detyrosinated α-tubulin (abbreviated to ligated-nitrotyrosine). Nitrotyrosine is produced by oxidative stress and is associated with cancer progression. Ligation of nitrotyrosine has been postulated to be a check-point induced by excessive cell stress. We found that the cytotoxicities of nitrotyrosine and tubulin poisons are independent of one another, suggesting that drugs that increase nitrotyrosination could be complementary to current tubulin-directed therapeutics. TTLL12 suppression of nitrotyrosination of α-tubulin was used to develop a robust cell-based ELISA assay that detects increased nitrotyrosination in cells that overexpress TTLL12 We adapted it to a high throughput format and used it to screen a 10,000 molecule World Biological Diversity SETTM collection of low-molecular weight molecules. Two molecules were identified that robustly activate nitrotyrosine ligation at 1 µM concentration. This is the pioneer screen for molecules that modulate nitrotyrosination of α-tubulin. The molecules from the screen will be useful for the study of TTLL12, as well as leads for the development of drugs to treat cancer and other pathologies that involve nitrotyrosination.
Subject(s)
Neoplasms , Tubulin , Tyrosine/analogs & derivatives , Humans , Tyrosine/pharmacology , Cell Division , MicrotubulesABSTRACT
In parallel with the inconsistency in observational studies and chemoprevention trials, the mechanisms by which selenium affects prostate cancer risk have not been elucidated. We conducted a randomized, placebo-controlled trial to examine the effects of a short-term intervention with selenium on gene expression in non-malignant prostate tissue. Twenty-three men received 300 µg selenium per day in the form of selenized yeast (n=12) or a placebo (n=11) during 5 weeks. Prostate biopsies collected from the transition zone before and after intervention were analysed for 15 participants (n=8 selenium, n=7 placebo). Pathway analyses revealed that the intervention with selenium was associated with down-regulated expression of genes involved in cellular migration, invasion, remodeling and immune responses. Specifically, expression of well-established epithelial markers, such as E-cadherin and epithelial cell adhesion molecule EPCAM, was up-regulated, while the mesenchymal markers vimentin and fibronectin were down-regulated after intervention with selenium. This implies an inhibitory effect of selenium on the epithelial-to-mesenchymal transition (EMT). Moreover, selenium was associated with down-regulated expression of genes involved in wound healing and inflammation; processes which are both related to EMT. In conclusion, our explorative data showed that selenium affected expression of genes implicated in EMT in the transition zone of the prostate.
Subject(s)
Dietary Supplements , Epithelial-Mesenchymal Transition/drug effects , Gene Expression Regulation/drug effects , Prostate/drug effects , Selenium/administration & dosage , Aged , Epithelial-Mesenchymal Transition/genetics , Gene Expression Profiling/methods , Gene Regulatory Networks , Humans , Male , Middle Aged , Netherlands , Oligonucleotide Array Sequence Analysis , Prostate/metabolism , Prostate/pathology , Signal Transduction/drug effects , Signal Transduction/genetics , Time Factors , TranscriptomeABSTRACT
Transcription factors have an important role in cancer but are difficult targets for the development of tumour therapies. These factors include the Ets family, and in this study Elk3 that is activated by Ras oncogene /Erk signalling, and is involved in angiogenesis, malignant progression and epithelial-mesenchymal type processes. We previously described the identification and in-vitro characterisation of an inhibitor of Ras / Erk activation of Elk3 that also affects microtubules, XRP44X. We now report an initial characterisation of the effects of XRP44X in-vivo on tumour growth and metastasis in three preclinical models mouse models, subcutaneous xenografts, intra-cardiac injection-bone metastasis and the TRAMP transgenic mouse model of prostate cancer progression. XRP44X inhibits tumour growth and metastasis, with limited toxicity. Tumours from XRP44X-treated animals have decreased expression of genes containing Elk3-like binding motifs in their promoters, Elk3 protein and phosphorylated Elk3, suggesting that perhaps XRP44X acts in part by inhibiting the activity of Elk3. Further studies are now warranted to develop XRP44X for tumour therapy.
Subject(s)
Antineoplastic Agents/pharmacology , Bone Neoplasms/drug therapy , Gene Expression Regulation, Neoplastic , Piperazines/pharmacology , Prostatic Neoplasms/drug therapy , Proto-Oncogene Proteins c-ets/antagonists & inhibitors , Pyrazoles/pharmacology , Animals , Bone Neoplasms/genetics , Bone Neoplasms/metabolism , Bone Neoplasms/secondary , Cell Line, Tumor , Drug Evaluation, Preclinical , Female , Genes, ras/drug effects , Heart Ventricles/metabolism , Heart Ventricles/pathology , Injections, Subcutaneous , Male , Mice , Mice, Inbred BALB C , Mice, Nude , Mice, Transgenic , Microtubules/drug effects , Mitogen-Activated Protein Kinase 1/antagonists & inhibitors , Mitogen-Activated Protein Kinase 1/genetics , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/antagonists & inhibitors , Mitogen-Activated Protein Kinase 3/genetics , Mitogen-Activated Protein Kinase 3/metabolism , Neuroglia/drug effects , Neuroglia/metabolism , Neuroglia/pathology , Prostatic Neoplasms/genetics , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology , Proto-Oncogene Proteins c-ets/genetics , Proto-Oncogene Proteins c-ets/metabolism , Rats , Signal Transduction , Tumor Burden/drug effects , Xenograft Model Antitumor AssaysABSTRACT
OBJECTIVE: We investigated whether dietary carotenoid and vitamin intake and supplemental vitamin use were inversely associated with RCC risk and with Von Hippel-Lindau (VHL)-gene mutations in clear-cell renal cell carcinoma (RCC). METHODS: The Netherlands Cohort Study on diet and cancer (NLCS) includes 120,852 persons, who completed a self-administered food-frequency questionnaire in 1986. After 11.3 years of follow-up, 284 cases and a random sample of 4,095 persons (subcohort) with complete data were included in multivariable analyses using a case-cohort approach. VHL gene mutational analysis was complete for 225 cases. Rate ratios and corresponding 95% confidence intervals were estimated using Cox proportional hazard models, while adjusting for age, sex, smoking, body mass index, and a history of hypertension. RESULTS: We observed no association for dietary carotenoid and vitamin intake and RCC risk, and a somewhat increased risk with supplemental vitamin E, AD, and multivitamin use. Results were suggestive of higher RRs for alpha-carotene, beta-cryptoxanthin, folate, and supplemental vitamin C and multivitamin intake for wildtype VHL tumors compared to VHL-mutated tumors. CONCLUSIONS: There was no association of carotenoid, vitamin or supplemental vitamin intake and RCC risk. These associations should be investigated by others to confirm the current observations.
Subject(s)
Carcinoma, Renal Cell/prevention & control , Carotenoids/therapeutic use , Kidney Neoplasms/prevention & control , Vitamins/therapeutic use , von Hippel-Lindau Disease/genetics , Aged , Carcinoma, Renal Cell/epidemiology , Carcinoma, Renal Cell/genetics , Case-Control Studies , Cohort Studies , Dietary Supplements , Female , Humans , Kidney Neoplasms/genetics , Male , Middle Aged , Netherlands/epidemiology , Nutrition Surveys , Proportional Hazards Models , RiskABSTRACT
PURPOSE: Hyperthermia combined with chemotherapy is not a novel cancer treatment. However, the working mechanism of this combination therapy is not fully understood. In the current in vitro study we investigated the differences in cytotoxicity of 4 chemotherapeutic agents at 37C or 43C. MATERIALS AND METHODS: The human transitional cell carcinoma cell lines used were RT4, RT112, 253J and T24. Cells were seeded in 96-well microtiter plates. After 24 hours cells were treated for 60 minutes with increasing concentrations of mitomycin C, epirubicin, gemcitabine and EO9 at a temperature of 37C or 43C. After treatment cells were rinsed 3 times and left for 24 hours in the incubator at 37C. The influence of chemotherapy and temperature on cell survival was determined by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide) assay. RESULTS: Decreased cell proliferation with increasing concentrations of chemotherapeutic agents was demonstrated. EO9 proved to be the most potent agent at each temperature. Hyperthermia alone did not demonstrate decreased cell proliferation. However, a synergistic effect on decreased cell proliferation was demonstrated in all cell lines and chemotherapeutic agents used, although each had a maximum at a different chemotherapy concentration and to a different extent. Synergism was most obvious in cell lines treated with low dose epirubicin. CONCLUSIONS: Synergism with hyperthermia and chemotherapy was clearly demonstrated for epirubicin, EO9, mitomycin C and to a lesser extent gemcitabine. Hyperthermia alone did not cause decreased cell proliferation. Synergism was most prominent with low drug doses and the most potent drug used in this in vitro study was EO9.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Transitional Cell/therapy , Deoxycytidine/analogs & derivatives , Hyperthermia, Induced , Urinary Bladder Neoplasms/therapy , Antibiotics, Antineoplastic/administration & dosage , Antimetabolites, Antineoplastic/administration & dosage , Antineoplastic Agents/administration & dosage , Aziridines/administration & dosage , Carcinoma, Transitional Cell/drug therapy , Carcinoma, Transitional Cell/pathology , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Survival/drug effects , Coloring Agents , Combined Modality Therapy , Deoxycytidine/administration & dosage , Epirubicin/administration & dosage , Humans , Indolequinones/administration & dosage , Mitomycin/administration & dosage , Tetrazolium Salts , Thiazoles , Urinary Bladder Neoplasms/drug therapy , Urinary Bladder Neoplasms/pathology , GemcitabineABSTRACT
INTRODUCTION: Hyperthermia and mitomycin-C (MMC) have given very encouraging results in several clinical studies for the treatment of superficial transitional cell carcinoma of the bladder. However, a synergistic effect of hyperthermia and MMC on the decrease of cell proliferation has never been demonstrated accurately in vitro. We investigated the effect of MMC versus MMC combined with hyperthermia on the cytotoxicity in four human bladder cancer cell lines. MATERIAL AND METHODS: The RT112, RT4, 253J and T24 human bladder cancer cell lines were seeded in 96-well microtiter plates at 2.0 x 10(4) cells per well and were left to attach for 24 hours. The cells were then treated for 60 minutes with MMC concentrations ranging from 0 to 400 microg/ml at a temperature of 37 degrees C or 43 degrees C. After treatment cells were rinsed three times with culture medium and left for 24 hours in the incubator. Dimethyl thiazolyl tetrazolium (MTT) solution was added and after 4 hours of incubation the MTT containing media was aspired from all wells and 100 microl of dimethyl sulfoxide was added to each well. A spectrum analyses was performed at 595 nm light wavelength. RESULTS: A decrease of cell proliferation after treatment with increasing concentrations MMC was demonstrated. Hyperthermia has a synergistic effect on the decrease of cell proliferation by different concentrations MMC. In the cells treated without MMC no significant difference in the extent of cell killing at 37 degrees C and 43 degrees C was observed. Furthermore, no difference was observed between cells with a p53 protein mutation (RT112 and T24) or without a p53 protein mutation (253J and RT4). CONCLUSION: A clear synergistic effect of MMC and hyperthermia has been demonstrated in four human bladder cancer cell lines.